Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recommended statin therapy. METHODS: We conducted a randomized, controlled trial involving patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both. Patients had to have an LDL cholesterol level of at least 70 mg per deciliter while they were receiving maximally tolerated statin therapy with or without additional lipid-lowering therapy. (Maximally tolerated statin therapy was defined as the highest intensity statin regimen that a patient was able to maintain, as determined by the investigator.) Patients were randomly assigned in a 2:1 ratio to receive bempedoic acid or placebo. The primary end point was safety, and the principal secondary end point (principal efficacy end point) was the percentage change in the LDL cholesterol level at week 12 of 52 weeks. RESULTS: The trial involved 2230 patients, of whom 1488 were assigned to receive bempedoic acid and 742 to receive placebo. The mean (±SD) LDL cholesterol level at baseline was 103.2±29.4 mg per deciliter. The incidence of adverse events (1167 of 1487 patients [78.5%] in the bempedoic acid group and 584 of 742 [78.7%] in the placebo group) and serious adverse events (216 patients [14.5%] and 104 [14.0%], respectively) did not differ substantially between the two groups during the intervention period, but the incidence of adverse events leading to discontinuation of the regimen was higher in the bempedoic acid group than in the placebo group (162 patients [10.9%] vs. 53 [7.1%]), as was the incidence of gout (18 patients [1.2%] vs. 2 [0.3%]). At week 12, bempedoic acid reduced the mean LDL cholesterol level by 19.2 mg per deciliter, representing a change of -16.5% from baseline (difference vs. placebo in change from baseline, -18.1 percentage points; 95% confidence interval, -20.0 to -16.1; P<0.001). Safety and efficacy findings were consistent, regardless of the intensity of background statin therapy. CONCLUSIONS: In this 52-week trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo and led to significantly lower LDL cholesterol levels. (Funded by Esperion Therapeutics; CLEAR Harmony ClinicalTrials.gov number, NCT02666664.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CLEAR Harmony trial assessed bempedoic acid’s safety and efficacy in 2230 statin-treated patients with atherosclerosis or HeFH compared with placebo [130]. Relative to placebo, bempedoic acid reduced LDL-C by − 16%, non-HDL-C by − 13%, total cholesterol by − 11%, ApoB-100 by − 12% and hsCRP by − 22%.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“The incidence of adverse events was similar across both interventional groups, yet a higher percentage discounted treatment with bempedoic acid than placebo (10.9% versus 7.1%). Gout was more frequently observed among patients treated with bempedoic acid (1.2% versus 0.3%).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [130]
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“Safety findings in the real-world setting were generally aligned with those reported in RCTs and meta-analyses [[12], [13], [14], [15],17,18], although reporting was limited and inconsistently captured.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [14]
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzymatic Determination of Total Serum Cholesterol
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,125
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
A peroxidase-coupled method for the colorimetric determination of serum triglycerides.
McGowan, M. W., Artiss, J. D., Strandbergh, D. R., & Zak, B. (1983) · Clinical Chemistry · doi:10.1093/clinchem/29.3.538 · Cited by 1,298
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Self-citationBallantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Self-citationMendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D. R., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 342
Self-citation
Cited by
Items 601–700 of 807
Serhiyenko, V. A., & Serhiyenko, A. A. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1275 · Cited by 1
Cesaro, A., Scherillo, G., Michele, G. D., Acerbo, V., Signore, G., Panico, D., Porcelli, G., Scialla, F., Raucci, G., Rotolo, F. P., et al. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.35 · Cited by 1
Dey, H., Agarwal, V., Ali, M. N., Upadhyay, A., Shafieq, S., Dixit, B., Tomar, S., & Tarannum, M. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i4.6533 · Cited by 1
“53 Muscle-related symptoms, such as myalgia and weakness, have been reported, although they are generally mild and transient.”
BackgroundBempedoic Acid in Secondary Prevention
Mousavi, I., Nambi, V., Abushamat, L. A., Al-Kindi, S. G., Shapiro, M. D., Sperling, L. S., Virani, S. S., & Minhas, A. M. K. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100715 · Cited by 1
“%) p-interaction = 0.43) [13].”
InfluentialEfficacy and Safety of Bempedoic Acid in Lipid Disorder Therapy: A Review of Clinical Trials
Dąbrowska, P., Żuber, M., & Dacka, M. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.208 · Cited by 1
“…większej częstości występowania ogólnych działań niepożądanych niż placebo i prowadził do istotnie niższego stężenia cholesterolu LDL. Efekt terapeutyczny utrzymywały się przez 52 tygodnie obserwacji, przy minimalnym osłabieniu efektu w analizach przebiegu leczenia w okresie 52 tygodni [31].”
Management of cardiometabolic diseases: A clinician's perspective
Bassi, N. S., Mohan, P., & Itchhaporia, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00002-4 · Cited by 1
Discovery of Alkyl Conjugated Diene Diacids as Novel ACLY Inhibitors
Cheng, T., Song, G., Cheng, L., Wang, F., Sun, X., Xie, Z., Zhang, M., Zhang, Y., Li, J., & Nan, F. (2024) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202405036 · Cited by 1
Ferrara, F., Zovi, A., Langella, R., Panico, A., Scognamiglio, M., Trama, U., Nava, E., Capuozzo, M., Primiano, F., & Russo, G. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03862-0 · Cited by 1
Ferrara, F., Zovi, A., Langella, R., Panico, A., Scognamiglio, M., Trama, U., Nava, E., Capuozzo, M., Primiano, F., & Russo, G. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2493728 · Cited by 2
“Bempedoic acid, which inhibits ATP citrate lyase, offers another option, particularly for statin-intolerant patients, providing effective LDL-C lowering without exacerbating muscle-related side effects [10].”
Ferrara, F., Zovi, A., Langella, R., Panico, A., Scognamiglio, M., Trama, U., Nava, E., Capuozzo, M., Primiano, F., & Russo, G. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2025.05.002 · Cited by 2
ESC-Leitlinien-Update 2025 zur Dyslipidämie
Hohneck, A., & Weingärtner, O. (2025) · Herz · doi:10.1007/s00059-025-05354-6 · Cited by 1
Julve, J., Rodríguez‐Calvo, R., Perret, B., Martinez, L. O., & Mauricio, D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248777 · Cited by 1
LDL-C lowering in patients treated with bempedoic acid in a real-world cohort
Nelson, J., Bloedon, L., Lewandowski, D., Vaduganathan, M., Ajose, M., Bonafede, M., & Sarnes, E. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.01.007 · Cited by 2
“In adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic CVD (ASCVD) who were on maximally tolerated statin therapy, BA provided additional LDL-C reduction of 15% to 17% from baseline to week 12 [14, 15].”
Self-citationBouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101725 · Cited by 3
RNA interference for lipid disorders: is this the future?
Nassif, M., Fazoli, R. T., & Generoso, G. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001033 · Cited by 1
Wang, J., Shi, X., Wang, D., Gao, J., Huang, K., Li, J., Dong, W., Li, Y., Guo, H., Wang, Y., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06094-4 · Cited by 2
“Consequently, many patients face a considerable risk of cardiovascular events even when their serum lipid concentration is controlled at very low levels [ 5, 6].”
Ray, K., Aguiar, C., Arca, M., Connolly, D., Eriksson, M., Ferriéres, J., Laufs, U., Mostaza, J., Nanchen, D., Boachie, C., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101577 · Cited by 1
“[29,30] and Pool 2 (CLEAR Serenity and Tranquility studies) — patients treated with low-dose or no statin therapy (mean LDL-C reduction, 24.1 %; SD, 22.3”
InfluentialSelf-citationEmerging roles of ATP citrate lyase in kidney diseases: from pathogenic driver to therapeutic target
Wei, M., Tao, M., Tan, H., Jin, Z., Yang, Y., Xiao, Z., Li, G., & Chen, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2652826 · Cited by 1
“…furthermore, a study of 2230 patients with atherosclerotic cardiovascular disease and hypercholesterolemia confirmed that adding bempedoic acid to maximally tolerated statin therapy significantly lowered LDL-C levels without increasing the overall rate of adverse events compared to placebo [110].”
LDL-Cholesterol Lowering Therapies: An Update
Humphrey, R., & Bowman, L. J. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53219 · Cited by 2
Federici, M., Buzzetti, R., Candido, R., Cosmo, S. D., Pirillo, A., Russo, G., Sesti, G., & Avogaro, A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03185-1 · Cited by 1
“Clinical trials have demonstrated that bempedoic acid provides an additional 18–25% LDL-C reduction when added to background lipid-lowering therapy, with a favourable safety profile [76, 77].”
Ciaula, A. D., Khalil, M., Garruti, G., & Portincasa, P. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101056 · Cited by 2
Hsieh, I.-C., Chen, D., Chu, C., Chang, Y., Tzeng, B., Huang, T., Lin, H., Chuang, W., Huang, C., Yeh, J., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049917 · Cited by 3
Bonaca, M. P., Canonico, M. E., Li, N., Sasiela, W. J., Nissen, S. E., Lincoff, A. M., & Nicholls, S. J. (2026) · Circulation · doi:10.1161/circulationaha.125.078469 · Cited by 2
“12,13 Recently the CLEAR Outcomes trial (Cholesterol Lowering via Bempedoic Acid [ETC1002], an ACL-Inhibiting Regimen) demonstrated that bempedoic acid reduces MACE in patients with established atherosclerotic vascular disease or at high risk for cardiovascular disease.”
Current and Emerging Therapies for Atherosclerosis
Nelson, A. J., & Nicholls, S. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-43683-4_4 · Cited by 2
Bempedoic acid for primary hypercholesterolaemia
Chaplin, S. (2021) · Prescriber · doi:10.1002/psb.1888 · Cited by 2
Estado autonómico y poder judicial
Mestre, J. B. I. (2002) · Dialnet (Universidad de la Rioja) · Cited by 4
Baessler, A., & Fischer, M. (2022) · Herz · doi:10.1007/s00059-022-05111-z · Cited by 2
“Für einen Einschluss in die Studie CLEAR HARMONY oder CLEAR WISDOM mussten die Patienten zudem eine über mindestens 4 Wochen vor dem Screening stabile maximal Herz 3 · 2022 215 Schwerpunkt Abb.”
BackgroundInfluentialImpact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors
Seijas‐Amigo, J., Gayoso-Rey, M., Mauriz-Montero, M. J., Suárez‐Artime, P., Casas-Martínez, A., Dominguez-Guerra, M., González-Freire, L., Estany-Gestal, A., Codero-Fort, A., Rodríguez‐Mañero, M., et al. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.08.002 · Cited by 1
Lipid modification in people with diabetes
Morris, D. (2023) · Prescriber · doi:10.1002/psb.2053 · Cited by 1
Connolly, D. L., Zaman, A., Capps, N. E., Bain, S. C., & Fernando, K. (2023) · British Journal of Cardiology · doi:10.5837/bjc.2023.014 · Cited by 3
Albackr, H. B., Waili, K. A., Almahmeed, W. A., Jarallah, M. A., Amin, M., Al‐Rasadi, K., Batais, M. A., Almigbal, T. H., Youssef, A. A., AlGhamdi, M. A., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230710145604 · Cited by 3
Modern prospects of targeted hypolipidemic therapy
Kuchmin, A. N., Борисович, Н. М., Grachev, A. M., & Смирнова, Е. В. (2023) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma321350 · Cited by 1
Lipidmanagement zur Reduktion des kardiovaskulären Risikos bei Typ-2-Diabetes
Brandts, J. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01094-5 · Cited by 1
“Bislang hat sich Bempedoinsäure als sicher und gut verträglich erwiesen [11, 15].”
BackgroundBempedoic Acid: Safety and Efficiacy of a New Lipid-Lowering Agent
Мазеркина, И. А., Букатина, Т. М., & Aleksandrova, T. V. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-3-292-302 · Cited by 1
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
“Manganese bullet” targeting for dyslipidemia and plaque reversal
Luo, F., Wang, Y., Wang, X., & Chen, X. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1146 · Cited by 1
Effect of statin add-on therapy on cardiovascular mortality
Nelson, J. R., Le, V. T., Anderson, J. L., & Ciffone, N. A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1308695 · Cited by 1
Pharmacotherapies for Cardiovascular Disease Prevention
Ballard‐Hernandez, J., & Irwin, C. W. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_14 · Cited by 1
Sallam, M., Hassan, H., Connolly, D. L., & Rahman, M. S. (2024) · European Cardiology Review · doi:10.15420/ecr.2024.06 · Cited by 2
Stoll, F., Amato, S., Sauter, M., Burhenne, J., Weiß, J., Haefeli, W. E., & Blank, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010060 · Cited by 1
Bempedoic acid after statin-induced rhabdomyolysis
Irene, V., & Alex, H. (2024) · Acta Clinica Belgica · doi:10.1080/17843286.2025.2480697 · Cited by 1
“Patients were also excluded in case of unexplained CK > 3× ULN at screening up to randomization (i.e. not associated with recent trauma or physically strenuous activity) [2].”
Severe HDL Cholesterol Reduction with Bempedoic Acid and Fenofibrate
Sbrana, F., Bigazzi, F., & Pino, B. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2413726 · Cited by 1
Raja, S. G. (2025) · British journal of healthcare and medical research · doi:10.14738/bjhmr.1202.18663 · Cited by 1
“Bempedoic acid differs from statins by inhibiting cholesterol synthesis at an earlier step in the enzymatic chain, thereby avoiding muscular side effects linked to statins and improving tolerance in patients with statin-induced myopathy [7].”
Sell, J. K., & Nunez, J. J. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197812631.003.0029 · Cited by 1
Behandlungsoptionen bei schweren Hypercholesterinämien
Vogt, A. (2019) · CardioVasc · doi:10.1007/s15027-019-1672-4 · Cited by 1
“In einer Studie, in die wenige Teilnehmer mit heFH eingeschlossen waren, wurde LDL-C bis zu 16,5 % gesenkt [24].”
BackgroundBegründung für die neuen LDL-Cholesterin-Zielwerte
Otto, S., Schulze, P. C., & Weingärtner, O. (2020) · Aktuelle Kardiologie · doi:10.1055/a-1200-1322 · Cited by 1
“In placebokontrollierten Studien konnte eine signifikante 18–28%ige LDL‐C-Senkung in Kombination mit hoch- oder niedrigdosierten Statinen und eine bis zu 38%ige LDL‐C-Reduktion in Kombination mit Ezetimib nachgewiesen werden [32,33].”
BackgroundHypercholesterinämie - Wie erreiche ich ein LDL < 55 mg/dl?
Vogt, A. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-4373-0 · Cited by 1
Defining the role of bempedoic acid in lowering low-density lipoprotein cholesterol
Korzh, O. (2020) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2020.101217 · Cited by 2
“…Patients with Hyperlipidemia and High Cardiovascular Risk), patients who received maximally tolerated therapy with statins treated with BemA had significantly lower LDL cholesterol than which received a placebo (mean difference, 18%), without an increase in serious side effects (Ray et al., 2019).”
BackgroundThe insidious impact of under-diagnosed proximal weakness induced by statins
Dobkin, B. H. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1866988 · Cited by 1
“This low estimate, however, may be based on imprecise reports of adverse effects during statin versus placebo-controlled, randomized clinical trials (RCTs), especially in regard to demonstrable weakness.”
BackgroundInfluentialWelche Risikofaktoren gibt es und was kann man dagegen tun?
Hambrecht, R., & Wienbergen, H. (2021) · Springer eBooks · doi:10.1007/978-3-662-63467-7_2 · Cited by 1
Oroko, M., & Fisher, M. (2022) · Practical Diabetes · doi:10.1002/pdi.2380 · Cited by 1
SOP Der herzkranke Diabetespatient
Gollmer, J., Zirlik, A., & Bugger, H. (2022) · Kardiologie up2date · doi:10.1055/a-1224-0954 · Cited by 1
Severe hypertriglyceridemia after use of bempedoic acid
Bovy, V., & Bogaert, A.-M. (2023) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2023_003838 · Cited by 1
Anti-inflammatory Therapy for Cardiovascular Disease
Ridker, P. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00024-8 · Cited by 1
High-Sensitivity C-Reactive Protein
David I. Feldman, Blumenthal, R. S., & Gluckman, T. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00008-x · Cited by 1
Future Energy Supply, Simulations with Limited Resources
Benichou, L. (2011) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Statin Intolerance, Bempedoic Acid, and Cardiovascular Outcomes
Lopez-Ayala, P., Glarner, N., & Mueller, C. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2305917 · Cited by 1
Viljoen, A., Handhle, A., & Wierzbicki, A. S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch48 · Cited by 1
Exploring a New “Reef” in Dyslipidemic Risk Reduction
Boden, W. E. (2026) · New England Journal of Medicine · doi:10.1056/nejme2516860 · Cited by 1
Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca
Frías, P. T., Ruíz, R. C., Duque, J. A. A., Senén, A. B., Olmo, M. R. F., & Jiménez, M. A. (2019) · REC CardioClinics · doi:10.1016/j.rccl.2019.01.007 · Cited by 2
Cardiology update - The first quarter
Yadav, S., Farooqui, F. A., & Singh, S. (2019) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_24_19
Update on genetics and molecular biology
Santos, R. D., & Chacra, A. P. M. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000633
Preventive cardiology: what the interventional cardiologist needs to know in 2019
McEvoy, J. W., & Mylotte, D. (2019) · EuroIntervention · doi:10.4244/eijv15i5a70
Encouragement of Super-aggressive LDL-lowering Therapies
Tada, H., Sakata, K., Takamura, M., & Kawashiri, M. (2019) · Journal of Coronary Artery Disease · doi:10.7793/jcad.25.19-00005
Tokgözoğlu, L. S., & Koçyiğit, D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320919867
An Integral Approach for Understanding the Bioactive Small Molecules in Cardiovascular DiseasesPreprint
Chen, Y. (2020) · doi:10.22541/au.158861363.33722117
“Recently new evidence has shown that the addition of bempedoic acid can reduce LDL-C level significantly among patients receiving maximally tolerated statins over 12 weeks in the phase III clinical trials [16] and more trials on its safety and efficacy are still ongoing [17].”
BackgroundUpdate Lipidologie: Evidenzbasierte Behandlung von Fettstoffwechselstörungen
Parhofer, K. G. (2020) · Der Internist · doi:10.1007/s00108-020-00799-9
Challenges in constructing genetic instruments for pharmacologic therapiesPreprint
Ference, B. A., Smith, G. D., Holmes, M. V., Catapano, A. L., Ray, K. K., & Nicholls, S. J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.13115 · Cited by 1
Self-citationBempedoic acid: A new player in lipid-lowering therapies
Cuevas, A. M., & Rodrigo Alonso, K. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.08.014
Perspektiven neuer lipidsenkender Substanzen für die Praxis
Klose, G. (2020) · CardioVasc · doi:10.1007/s15027-020-3424-x
“1 aufgeführten Studien im CLEAR-Programm (Cholesterol Lowering via Bempedoic Acid, an ACL Inhibiting Regimen) [3, 4, 5, 6].”
BackgroundSinning, D., & Landmesser, U. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1199-8496
“[34] Ray KK, Bays HE, Catapano AL et al.”
BackgroundBempedoinsäure – ein neuer Spieler in der Lipidtherapie
Eggebrecht, H. (2021) · Der Kardiologe · doi:10.1007/s12181-021-00447-y
Emerging New Lipid-Lowering Therapies in the Statin Era
Jang, A. Y., Jo, S., & Koh, K. K. (2021) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2021.1.e5
A new player in the fight against dyslipidemia – bempedoic acid
Blödt, K. (2021) · VASA · doi:10.1024/0301-1526/a000930
Hussar, D. A., & Finn, L. A. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.176
General Perspectives for the Treatment of Atherosclerosis
Gülcan, H. O., & Orhan, İ. E. (2020) · Letters in Drug Design & Discovery · doi:10.2174/1570180817999201016154400
Desarrollo clínico de ácido bempedoico: estudios fase 2 y fase 3
Lekuona, I., & Pintó, X. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.005 · Cited by 1
Bempedoic Acid: A First-in-Class Agent for Lowering Cholesterol Levels
McGraw-Senat, C. M., Dillard, N., Guelda, T., Samuel, E., & Ling, H. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.331
Statin Intolerance: Alternative Therapy for Lipid Management
Cross, L. V., & Mattingly, J. (2021) · ADCES in Practice · doi:10.1177/2633559x20972355
“1).(9) There was no substantial difference in the incidence of adverse events, but the incidence of gout was higher in the bempedoic acid group compared to placebo (1.”
BackgroundFatty acid synthesis and prostate cancer
Koltai, T., Reshkin, S. J., Baltazar, F., & Fliegel, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90528-2.00004-7
Zhou, G., Wang, P., Lu, S., Wang, C., Xie, Z., Cao, W., Shi, J., Zhu, W., Wang, R., Zhou, G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3911102
Bempedoic acid: LDL-C lowering without adverse reactions
Whitney, K. R. (2021) · JAAPA · doi:10.1097/01.jaa.0000795036.55877.c8
De toepasbaarheid van de SUR-meting voor ultrafiltratie van rwzi-effluent
Janssen, A. N., & van der Graaf, J. H. J. M. (2012) · Research Repository (Delft University of Technology)
Hein, L., & Seifert, R. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_2
Ácido bempedoico en pacientes con diabetes tipo 2
Masson, W. M., Barbagelata, L., Lobo, M., & Nogueira, J. P. (2022) · Revista Clínica Española · doi:10.1016/j.rce.2021.11.003
Lucchi, T. A. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch31
Xiong, J., Zhou, P., Jiang, H., Huang, T., He, Y., Zhao, Z., Zang, Y., Choo, Y., Wang, X., Chittiboyina, A. G., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202109082
Statine und neue Therapieoptionen zur Behandlung der LDL-Hypercholesterinämie
Katzmann, J. L., & Laufs, U. (2020) · Diabetes aktuell · doi:10.1055/a-1237-0720
“[13] Ray KK, Bays HE, Catapano AL et al.”
BackgroundInfluentialArvanitis, M., Post, W. S., & Battle, A. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_3
Selección de lo mejor del año 2019 en riesgo vascular y rehabilitación cardiaca
Arrarte, V., Campuzano, R., Carro, A., Castro, A., Dalmau, R., Sandín, M., Velasco, E., & Valle, A. (2019) · REC CardioClinics · doi:10.1016/j.rccl.2019.10.015
Medikamentöse Therapie der Fettstoffwechselstörungen im Kindesalter
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_5
Kirchner, J. T. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780197576595.003.0045
Masche, U. (2021) · pharma-kritik · doi:10.37667/pk.2021.1176
Abordagem atual das dislipidemias
Juliani, F. C., & Rocha, V. Z. (2021) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2021.20.4.20-31
Smuglov, E. P., Glushko, A., & Gordienko, V. (2022) · Таврический медико-биологический вестник · doi:10.29039/2070-8092-2020-23-1-140-147 · Cited by 1
Step-wise lipid-lowering therapy: thinking beyond the guidelines
Pingitore, A., Spadafora, L., Biondi‐Zoccai, G., & Giordano, A. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001388
Inclisiran, ARN interferente pequeño: un nuevo enfoque para el tratamiento del colesterol
Fragozo-Ramos, M. C., Gómez-Sierra, V., Gómez-Galvis, L. V., Campo, R., Santos, R. D., & Román-Gonzaléz, A. (2022) · Revista Colombiana de Cardiología · doi:10.24875/rccar.21000150
Romandini, A., Baldassarre, D., Genovese, S., Capri, S., Pompilio, G., Scatigna, M., & Werba, J. P. (2023) · Pharmaceuticals · doi:10.3390/ph16020176
Goldberg, A. C., Banach, M., Catapano, A. L., Duell, P. B., Leiter, L. A., Hanselman, J. C., Lei, L., & Mancini, G. B. J. (2023) · medRxiv · doi:10.1101/2023.02.14.23285912
“Women are less likely than men to receive guideline-recommended lipid-lowering therapies (LLTs), such as statins, and consequently less likely to achieve recommended low-density lipoprotein cholesterol (LDL-C) levels [6-9].”
BackgroundMethodInfluentialSelf-citationTherapieoptionen bei diabetischer Nephropathie
Morgenroth, R., Mertens, P. R., Herzog, C. A., & Scurt, F. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01003-w
“glykämischen Kontrolle bei [8, 9], kardiovaskuläre Endpunktstudien hierzu fehlen”
Background
Metadata
- Authors
- Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-14
- Volume
- 380
- Issue
- 11
- Pages
- 1022-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2922038538
- Cited by
- 807
- References
- 20
- Citations by year
- 2026: 77 · 2025: 87 · 2024: 114 · 2023: 143 · 2022: 116 · 2021: 107 · 2020: 107 · 2019: 53
- FWCI
- 91.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- bempedoic acid, LDL cholesterol lowering, ATP-citrate lyase inhibitor, hypercholesterolemia, atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, statin therapy, gout, adverse events, drug safety, lipid-lowering therapy, long-term treatment, gout risk, statin intolerance
- MeSH terms
- Aged, Apolipoproteins B, ATP Citrate (pro-S)-Lyase, C-Reactive Protein, Cholesterol, Dicarboxylic Acids, Drug Therapy, Combination, Fatty Acids, Female, Humans, Hypercholesterolemia, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Peptide Fragments, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.